Treatment of prosthetic osteoarticular infections

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 6, 2011, Pages 899-912

  Esteban, Jaime ^a   Cordero Ampuero, José ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

biofilm; bone and joint infection; daptomycin; intracellular; linezolid; multidrug resistant; prosthesis; treatment

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; FOSFOMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; ORITAVANCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ACUTE KIDNEY FAILURE; AGITATION; ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTHRODESIS; ARTHROPATHY; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BIOFILM; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; DEBRIDEMENT; DEVICE REMOVAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; FLU LIKE SYNDROME; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; HUMAN; HYPOKALEMIA; INTRACELLULAR BACTERIUM; JOINT PROSTHESIS; LEUKOPENIA; LIVER INJURY; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYOPATHY; NAUSEA; NEUTROPENIA; NONHUMAN; OPTIC NEURITIS; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHOTOTOXICITY; PROSTHESIS INFECTION; PSEUDOMEMBRANOUS COLITIS; REIMPLANTATION; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STEVENS JOHNSON SYNDROME; TENDON DISEASE; THROMBOCYTOPENIA; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREMOR;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BIOFILMS; CONSENSUS; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE; HUMANS; INTERDISCIPLINARY COMMUNICATION; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; PROSTHESIS-RELATED INFECTIONS; REOPERATION;

EID: 79952748288     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.543676     Document Type: Review

References (133)

1. Kurtz SM, Lau E, Schmier J, et al. Infection Burden for Hip and Knee Arthroplasty in the United States. J Arthroplasty 2008;12(7):984-91
2. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med 2004;350:1422-9 (Pubitemid 38419996)
3. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004;351:1645-54
4. Del Pozo JL, Patel R. Clinical practice. Infection associated with prosthetic joints. N Engl J Med 2009;361(8):787-94
5. Gristina AG. Biomaterial-centered infection: microbial adhesion versus tissue integration. Science 1987;237:1588-95 (Pubitemid 17134883)
6. Costerton JW, Geesey GG, Cheng KJ. How bacteria stick. Sci Am 1978;238(1):86-95
7. Costerton JW. The biofilm primer. Springer-Verlag, Berlin; 2007
8. Donlan RM. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis 2001;33:1387-92 (Pubitemid 32955193)
9. Costerton JW, Montanaro L, Arciola CR. Biofilm in implant infections: its production and regulation. Int J Artif Organs 2005;28:1062-8 (Pubitemid 43085399)
10. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2004;2:95-108 (Pubitemid 39490064)
11. Hall-Stoodley L, Stoodley P. Biofilm formation and dispersal and the transmission of human pathogens. Trends Microbiol 2005;13(1):7-10 (Pubitemid 40082390)
12. Katsikogianni M, Missirlis YF. Concise review of mechanisms of bacterial adhesion to biomaterial and of techniques used in estimating bacteria-material interactions. Eur Cells Mater 2004;8:37-57 (Pubitemid 40132321)
13. Darouiche RO. Device-associated infections: a macroproblem that starts with microadherence. Clin Infect Dis 2001;33:1567-72 (Pubitemid 34246153)
14. Donlan RM. Biofilms and device-associated infections. Emerg Infect Dis 2001;7(2):277-9
15. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002;15(2):167-93 (Pubitemid 34303762)
16. Esteban J, Molina-Manso D, Spiliopoulou I, et al. Biofilm development by clinical isolates of staphylococcus spp. from retrieved orthopaedic prosthesis. Acta Orthopaedica 2010; In press
17. Trampuz A, Widmer AF. Infections associated with orthopedic implants. Curr Opin Infect Dis 2006;19:349-56 (Pubitemid 43982507)
18. Trampuz A, Zimmerli W. Diagnosis and treatment of infections associated with fracture-fixation devices. Injury Int J Care Injured 2006;37:S59-66
19. Esteban J, Gomez-Barrena E, Cordero J, et al. Evaluation of quantitative cultures from sonicated retrieved orthopaedic implants in the diagnosis of orthopaedic infection. J Clin Microbiol 2008;46(2):488-92 (Pubitemid 351231291)
20. Trampuz A, Piper KE, Jacobson MJ, et al. Sonication of removed hip and knee prostheses for diagnosis of infection. N Engl J Med 2007;357(7):654-63 (Pubitemid 47267235)
21. Achermann Y, Vogt M, Leunig M, et al. Improved diagnosis of periprosthetic joint infection by multiplex PCR of sonication fluid from removed implants. J Clin Microbiol 2010;48(4):1208-14
22. Tunney MM, Patrick S, Curran MD, et al. Detection of prosthetic hip infection at revision arthroplasty by immunofluorescence microscopy and PCR amplification of the bacterial 16S rRNA gene. J Clin Microbiol 1999;37(10):3281-90 (Pubitemid 29455221)
23. Costerton JW. Biofilm theory can guide the treatment of device-related orthopaedic infections. Clin Orthop 2005;437:7-11 (Pubitemid 41099059)
24. Mah TC, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 2001;9(1):34-9
25. Olson ME, Ceri H, Morck DW, et al. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Canadian J Vet Res 2002;66:86-92 (Pubitemid 34568249)
26. Patel R. Biofilms and antimicrobial resistance. Clin Orthop Relat Res 2005;437:41-7 (Pubitemid 41099064)
27. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilm. Lancet 2001;358:135-8
28. Ceri H, Olson ME, Stremick C, et al. The calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999;37(6):1771-6 (Pubitemid 29235221)
29. Drancourt M, Stein A, Argenson JN, et al. Oral rifampin plus ofloxacin for treatment of staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother 1993;37:1214-18 (Pubitemid 23166716)
30. Southwood RT, Rice JL, McDonald PJ, et al. Infection in experimental arthroplasties. Clin Orthop Relat Res 1987;224:33-6 (Pubitemid 18003623)
31. Stein A, Bataille JF, Drancourt M, et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected ortohopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998;42:3086-91 (Pubitemid 28553722)
32. Proctor RA, van Langevelde P, Kristjansson M, et al. Persistent and relapsing infections associated with small-colony variants of staphylococcus aureus. Clin Infect Dis 1995;20:95-102
33. Tuchscherr L, Heitmann V, Hussain M, et al. Staphylococcus aureus small-colony variants are adapted phenotypes for intracellular persistence. J Infect Dis 2010;202(7):1031-40
34. Maurin M, Raoult D. Phagolysosomal alkalinization and intracellular killing of staphylococcus aureus by Amikacin. J Infect Dis 1994;169:330-6 (Pubitemid 24045592)
35. Cordero J. Infection of orthopaedic implants. Theory and practice. Eur Instr Course Lect 1999;4:165-73
36. Cordero J, Garcia-Cimbrelo E. Mechanisms of bacterial resistance in implant infection. Hip International 2000;10:139-44
37. Cordero-Ampuero J, Esteban J, Garcia-Cimbrelo E, et al. Low relapse with oral antibiotics and two-stage exchange for late arthroplasty infections in 40 patients after 2-9 years. Acta Orthopaedica 2007;78(4):511-19 (Pubitemid 350032287)
38. Sendi P, Rohrbach M, Graber P, et al. Staphylococcus aureus small colony variants in prosthetic joint infection. Clin Infect Dis 2006;43(8):961-7 (Pubitemid 44631093)
39. Ellington JK, Harris M, Hudson MC, et al. Intracellular Staphylococcus aureus and antibiotic resistance: implications for treatment of staphylococcal osteomyelitis. J Orthop Res 2006;24(1):87-93 (Pubitemid 43772612)
40. Barberan J, Aguilar L, Carroquino G, et al. Conservative treatment of staphylococcal prosthetic joint infections in elderly patients. Am J Med 2006;119(11): 993 e7-10
41. Murillo O, Domenech A, Euba G, et al. Efficacy of linezolid alone and in combination with rifampin in staphylococcal experimental foreign-body infection. J Infect 2008;57(3):229-35
42. Frippiat F, Meunier F, Derue G. Place of newer quinolones and rifampicin in the treatment of Gram-positive bone and joint infections. J Antimicrob Chemother 2004;54(6):1158, author reply 9
43. Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev 2010;23(1):14-34
44. Morales G, Picazo JJ, Baos E, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010;50(6):821-5
45. Baciewicz AM, Chrisman CR, Finch CK, et al. Update on rifampin and rifabutin drug interactions. Am J Med Sci 2008;335(2):126-36 (Pubitemid 351253409)
46. Rissing JP. Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones. Clin Infect Dis 1997;25:1327-33 (Pubitemid 28022665)
47. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Int Med 2003;138:135-42
48. Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother 2003;51(Suppl 2):ii9-16
49. Wallace RJ Jr, Brown-Elliott BA, Ward SC, et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001;45(3):764-7 (Pubitemid 32182022)
50. Kuli B, de Barbeyrac B, Dauchy FA, et al. In vitro activities of daptomycin, tigecycline, linezolid and eight other antibiotics, alone and in combination, against 41 Staphylococcus spp. clinical isolates from bone and joint infections. Int J Antimicrob Agents 2009;33(5):491-3
51. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrobial Chemother 2003;51(Suppl S2):ii17-25 (Pubitemid 36622108)
52. Venugopalan V, Martin CA. Selecting anti-infective agents for the treatment of bone infections: new anti-infective agents and chronic suppressive therapy. Orthopedics 2007;30(10):832-4 (Pubitemid 350032731)
53. French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003;51(Suppl 2):ii45-53 (Pubitemid 36622111)
54. Harwood PJ, Talbot C, Dimoutsos M, et al. Early experience with linezolid for infections in orthopaedics. Injury 2006;37(9):818-26 (Pubitemid 44223490)
55. Rao N, Hamilton CW. Efficacy and safety of linezolid for gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis 2007;59(2):173-9 (Pubitemid 47484126)
56. Papadopoulos A, Plachouras D, Giannitsioti E, et al. Efficacy and tolerability of linezolid in chronic osteomyelitis and prosthetic joint infections: a case-control study. J Chemother 2009;21(2):165-9
57. Soriano A, Gomez J, Gomez L, et al. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol Infect Dis 2007;26(5):353-6 (Pubitemid 46716796)
58. Bernard L, Stern R, Lew D, et al. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis 2003;36(9):1197 (Pubitemid 36549644)
59. Senneville E, Legout L, Valette M, et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006;28(8):1155-63 (Pubitemid 44374746)
60. Rayner CR, Baddour LM, Birmingham MC, et al. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 2004;32(1):8-14 (Pubitemid 38210506)
61. Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopedic infections. Mayo Clin Proc 2004;79(9):1137-44 (Pubitemid 39129476)
62. Rao N, Ziran BH, Hall RA, et al. Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop Relat Res 2004;427:67-71 (Pubitemid 39362833)
63. Bassetti M, Di Biagio A, Cenderello G, et al. Linezolid treatment of prosthetic hip Infections due to methicillin-resistant Staphylococcus aureus (MRSA). J Infect 2001;43(2):148-9
64. Bassetti M, Vitale F, Melica G, et al. Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother 2005;55(3):387-90 (Pubitemid 40425467)
65. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004;38(7):994-1000 (Pubitemid 38457208)
66. LaPlante KL, Rybak MJ. Daptomycin-a novel antibiotic against Gram-positive pathogens. Expert Opin Pharmacother 2004;5(11):2321-31 (Pubitemid 39489984)
67. Sauermann R, Rothenburger M, Graninger W, et al. Daptomycin: a review 4 years after first approval. Pharmacology 2008;81(2):79-91 (Pubitemid 351182681)
68. Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007;51(5):1656-60 (Pubitemid 46744141)
69. Murillo O, Garrigos C, Pachon ME, et al. Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant staphylococcus aureus. Antimicrob Agents Chemother 2009;53(10):4252-7
70. Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009;49(2):177-80
71. Vikram HR, Havill NL, Koeth LM, et al. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol 2005;43(10):5384-7 (Pubitemid 41484067)
72. Hayden MK, Rezai K, Hayes RA, et al. Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005;43(10):5285-7 (Pubitemid 41484040)
73. Falagas ME, Giannopoulou KP, Ntziora F, et al. Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int J Antimicrob Agents 2007;30(3):202-9 (Pubitemid 47126811)
74. Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections. Curr Med Res Opin 2005;21(12):1923-6 (Pubitemid 41803101)
75. Lalani T, Boucher HW, Cosgrove SE, et al. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008;61(1):177-82
76. Rice DA, Mendez-Vigo L. Daptomycin in bone and joint infections: a review of the literature. Arch Orthop Trauma Surg 2009;129(11):1495-504
77. Quetglas EG, San Julian M, Garcia Tutor E, et al. A long-term retrospective review of 5 cases using daptomycin for prosthetic device infections after surgery. Int J Artif Organs 2009;32(5):299-307
78. Bouza E, Burillo A. Oritavancin: a novel lipoglycopeptide active against gram-positive pathogens including multiresistant strains. Int J Antimicrob Agents 2010;36(5):401-7
79. Billeter M, Zervos MJ, Chen AY, et al. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic Clin Infect Dis 2008;46(4):577-83 (Pubitemid 351263500)
80. Decousser JW, Bourgeois-Nicolaos N, Doucet-Populaire F. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria. Expert Rev Anti Infect Ther 2007;5(4):557-71 (Pubitemid 47250131)
81. Pope SD, Roecker AM. Dalbavancin: a novel lipoglycopeptide antibacterial. Pharmacotherapy 2006;26(7):908-18
82. Roecker AM, Pope SD. Dalbavancin: a lipoglycopeptide antibacterial for Gram-positive infections. Expert Opin Pharmacother 2008;9(10):1745-54
83. Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010;70(7):859-86
84. Zhanel GG, Trapp S, Gin AS, et al. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of gram-positive infections. Expert Rev Anti Infect Ther 2008;6(1):67-81 (Pubitemid 351372579)
85. Biedenbach DJ, Jones RN. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007). Diagn Microbiol Infect Dis 2009;64(2):177-84
86. Goldstein BP, Draghi DC, Sheehan DJ, et al. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother 2007;51(4):1150-4 (Pubitemid 46586787)
87. Goldstein EJ, Citron DM, Warren YA, et al. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections. Antimicrob Agents Chemother 2006;50(8):2875-9 (Pubitemid 44198720)
88. Salvati EA, Della-Valle AG, Masri BA, et al. The infected total hip arthroplasty. Instr Course Lect 2003;52:223-46
89. Hoad-Reddick DA, Evans CR, Norman P, et al. Is there a role for extended antibiotic therapy in a two-stage revision of the infected knee arthroplasty? J Bone Joint Surg (Br) 2005;87-B:171-5
90. Lieberman JR, Callaway GH, Salvati EA, et al. Treatment of the infected total hip arthroplasty with a two-stage reimplantation protocol. Clin Orthop 1994;301:205-12 (Pubitemid 24119275)
91. Cierny GI, DiPasquale D. Periprosthetic total joint infections: staging, treatment, and outcomes. Clin Orthop 2002;403:23-8
92. Trebse R, Pisot V, Trampuz A. Treatment of infected retained implants. J Bone Joint Surg (Br) 2005;87-B:249-56 (Pubitemid 40278028)
93. Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998;279(19):1537-41 (Pubitemid 28233008)
94. Gristina AG, Costerton JW. Bacterial adherence to biomaterials and tissue. J Bone Joint Surg (Am) 1985;67-A:264-73
95. Gristina AG, Naylor PT, Myrvik QN. Mechanisms of musculoskeletal sepsis. Orthop Clin North Am 1991;22:363-71
96. Brandt CM, Sistrunk WW, Duffy MC, et al. Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention. Clin Infect Dis 1997;24:914-19 (Pubitemid 27193877)
97. Mader JT, Wang J, Calhoun JH. Antibiotic therapy for musculoskeletal infections. Instr Course Lect 2001;51:539-51
98. Hanssen AD, Rand JA. Evaluation and treatment of infection at the site of a total hip or knee arthroplasty. Instr Course Lect 1999;48:111-22
99. Garvin KL, Fitzgerald RH, Salvati EA. Reconstruction of the infected total hip and knee arthroplasty with gentamicin-impregnated Palacos bone cement. Instr Course Lect 1993;42:293-302
100. Raut VV, Siney PD, Wroblewsky BM. One-stage revision of infected total hip replacements with discharging sinuses. J Bone Joint Surg (Br) 1994;76:721-4 (Pubitemid 24289557)
101. Callaghan JJ, Katz RP, Johnston RC. One-stage revision surgery of the infected hip: A minimum 10-year followup study. Clin Orthop 1999;369:139-43
102. Haddad FS, Masri BA, Garbuz DS, et al. The treatment of the infected hip replacement: The complex case. Clin Orthop 1999;369:144-56
103. McDonald DJ, Fitzgerald RHJ, Ilstrup DM. Two-stage reconstruction of a total hip arthroplasty because of infection. J Bone Joint Surg (Am) 1989;71:828-34 (Pubitemid 19205262)
104. Garvin KL, Evans BG, Salvati EA, et al. Palacos gentamicin for the treatment of deep periprosthetic hip infections. Clin Orthop 1994;298:97-105 (Pubitemid 24023598)
105. Younger AS, Duncan CP, Masri BA, et al. The outcome of two-stage arthroplasty using a custom-made interval spacer to treat the infected hip. J Arthroplasty 1997;12:615-23 (Pubitemid 27427939)
106. Colyer RA, Capello WN. Surgical treatment of the infected hip implant: Two-stage reimplantation with a one-month interval. Clin Orthop 1994;298:75-9 (Pubitemid 24023595)
107. Lai KA, Shen WJ, Yanj CY, et al. Two-stage cementless revision THR after infection: 5 recurrences in 40 cases followed 2,5-7 years. Acta Orthop Scand 1996;67:325-8
108. Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty: a study of the treatment of one hundred and six infections. J Bone Joint Surg (Am) 1996;78:512-23 (Pubitemid 26115571)
109. Mont MA, Waldman BJ, Hungerford DS. Evaluation of preoperative cultures before second-stage reimplantation of a total knee prosthesis complicated by infection: A comparison-group study. J Bone Joint Surg (Am) 2000;82:1552-7
110. Wilde AH, Ruth JT. Two-stage reimplantation in infected total knee arthroplasty. Clin Orthop 1988;236:23-35 (Pubitemid 18264695)
111. Booth REJ, Lotke PA. The results of spacer block technique in revision of infected total knee arthroplasty. Clin Orthop 1989;248:57-60 (Pubitemid 20204781)
112. Cordero-Ampuero J, Esteban J, Garcia-Rey E. Results after late polymicrobial, gram-negative, and methicillin-resistant infections in knee arthroplasty. Clin Orthop Relat Res 2010;468(5):1229-36
113. Leone JM, Hanssen AD. Management of Infection at the Site of a total knee arthroplasty. Instr Course Lect 2006;55:449-61
114. Kordelle J, Frommelt L, Kluber D, et al. Results of one-stage endoprosthesis revision in periprosthetic infection cause by methicillin-resistant Staphylococcus aureus. Z Orthop Ihre Grenzgeb 2000;138(3):240-4 (Pubitemid 30462653)
115. Callaghan JJ, Katz RP, Johnston RC. One-stage revision surgery of the infected hip. A minimum 10-year followup study. Clin Orthop Relat Res 1999;369:139-43
116. Hirakawa K, Stulberg BN, Wilde AH, et al. Results of 2-stage reimplantation for infected total knee arthroplasty. J Arthroplasty 1998;13(1):22-8 (Pubitemid 28082632)
117. Volin SJ, Hinrichs SH, Garvin KL. Two-stage reimplantation oftotal joint infections: a comparison of resistant and non-resistant organisms. Clin Orthop Relat Res 2004;(427):94-100 (Pubitemid 39362837)
118. Segawa H, Tsukayama DT, Kyle RF, et al. Infection after total knee arthroplasty. A retrospective study of the treatment of eighty-one infections. J Bone Joint Surg Am 1999;81(10):1434-45 (Pubitemid 29489476)
119. Stockley I, Mockford BJ, Hoad-Reddick A, et al. The use of two-stage exchange arthroplasty with depot antibiotics in the absence of long-term antibiotic therapy in infected total hip replacement. J Bone Joint Surg Br 2008;90(2):145-8 (Pubitemid 351303337)
120. Hope PG, Kristinsson KG, Norman P, et al. Deep infection of cemented total hip arthroplasties caused by coagulase-negative Staphylococcus. J Bone Joint Surg (Br) 1989;71:851-5 (Pubitemid 19282581)
121. Kilgus DJ, Howe DJ, Strang A. Results of periprosthetic hip and knee infections caused by resistant bacteria. Clin Orthop 2002;404:116-24 (Pubitemid 35351060)
122. Mittal Y, Fehring TK, Hanssen A, et al. Two-stage reimplantation for periprosthetic knee infection involving resistant organisms. J Bone Joint SurgAm 2007;89(6):1227-31 (Pubitemid 46897993)
123. Cordero-Ampuero J, Esteban J, Garcia-Cimbrelo E. Oral antibiotics are effective for highly resistant hip arthroplasty infections. Clin Orthop Relat Res 2009;467(9):2335-42
124. Ghannoum M, O'Toole GA. Microbial biofilms. 1 edition. ASM Press, Washington, DC; 2004
125. Martins-Texeira L, Siqueira-Carvalho MG, Facklam RR. Enterococcus. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, editors. Manual of clinical microbiology. 9 edition. American Society of Microbiology, Washington, DC; 2007 pp. 430-42
126. Blondel-Hill E, Henry DA, Speert DP. Pseudomonas. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, editors. Manual of clinical microbiology. 9 edition. American Society of Microbiology,Washington, DC; 2007 pp. 734-48
127. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998;11(1):57-80 (Pubitemid 28046016)
128. Lewis G. Properties of antibiotic-loaded acrylic bone cements for use in cemented arthroplasties: a state-of-the-art review. J Biomed Mater Res B Appl Biomater 2009;89B(2):558-74
129. Andollina A, Bertoni G, Zolezzi C, et al. Vancomycin and meropenem in acrylic cement: elution kinetics of in vitro bactericidal action. Chir Organi Mov 2008;91(3):153-8
130. Weiss BD, Weiss EC, Haggard WO, et al. Optimized elution of daptomycin from polymethylmethacrylate beads. Antimicrob Agents Chemother 2009;53(1):264-6
131. Anguita-Alonso P, GiacomettiA, Cirioni O, et al. RNAIII-inhibiting- peptide-loaded polymethylmethacrylate prevents in vivo Staphylococcus aureus biofilm formation. Antimicrob Agents Chemother 2007;51(7):2594-6 (Pubitemid 47047343)
132. Vallet-Regi M, Balas F, Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Ed Engl 2007;46(40):7548-58 (Pubitemid 47556998)
133. Vallet-Regi M, Balas F, Colilla M, et al. Drug confinement and delivery in ceramic implants. Drug Metab Lett 2007;1(1):37-40